2172P - Development and evaluation of the usefulness of an immune-related adverse events interview application

Background

The use of immune checkpoint inhibitors (ICIs) needs monitoring for the development of serious immune-related adverse events (irAEs). Here, we developed a smartphone application (an irAEs self-reported interview system: ISRIS) to enable early detection of irAEs while outpatients are at home and evaluated its usefulness.

Methods

This investigation included outpatients who received ICIs between September 2020 and February 2023 and had the application installed on their smartphones. The investigation items included treatment regimen and its dosage, type of irAE and the grade, frequency of ISRIS usage, and sensitivity and specificity for detecting irAEs to evaluate the efficacy of our ISRIS system.

Results

In total, sixty-one patients (female/male: 13/39, mean age: 65 y.o., range: 26-87 y.o.) installed the application on their smartphones. irAEs occurred in twenty-four patients; the irAEs detectable by the app included interstitial pneumonia (n=7), thyroid dysfunction (n=4), skin disorders (n=4), adrenocortical dysfunction (n=3), colitis (n=2), myocarditis (n=1), uveitis (n=1), liver disorders (n=1), and Guillain-Barré syndrome (n=1). Among patients with irAEs, thirteen patients had installed the application at least one week before the irAE onset; of these, irAEs were detected by ISRIS in eight patients, indicating 62% sensitivity and 57% specificity, respectively.

Conclusions

Our ISRIS application for smartphones allows healthcare professionals to monitor the physical condition of patients with cancer in real time via self-reported interview data for early intervention, even when the patient is at home, facilitating the early detection and response to irAEs. In addition, having healthcare professionals review the results of the interview can reduce patient anxiety about adverse reactions, thereby contributing to treatment continuation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

A. Yano.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.